{"id":18977,"date":"2025-02-20T09:09:03","date_gmt":"2025-02-20T08:09:03","guid":{"rendered":"https:\/\/raue.com\/?p=18977"},"modified":"2025-02-20T09:09:03","modified_gmt":"2025-02-20T08:09:03","slug":"raue-advises-lauxera-capital-partners-on-50-million-euro-investment-in-acandis","status":"publish","type":"post","link":"https:\/\/raue.com\/en\/practices\/corporate-ma-finance\/raue-advises-lauxera-capital-partners-on-50-million-euro-investment-in-acandis\/","title":{"rendered":"Raue Advises Lauxera Capital Partners on 50 Million Euro Investment in Acandis"},"content":{"rendered":"<p>Raue has advised Lauxera Capital Partners on the due diligence of its 50 million Euro investment in Acandis GmbH. Acandis is a leading German neurovascular medical technology company specialising in the prevention and treatment of strokes.<\/p>\n<p>The Lauxera and Acandis transaction represents Lauxera&#8217;s first investment from its second-generation healthcare growth buyout fund, Lauxera Growth II.<\/p>\n<p>About Lauxera Capital Partners:<\/p>\n<p>Lauxera Capital Partners, founded in 2020, has established itself as a leading transatlantic investment firm in the healthcare sector and currently manages over 600 million Euro.<\/p>\n<p>About Acandis:<\/p>\n<p>Acandis was founded in 2006 by Dr Andreas and Kirsi Schuessler and is today a leading neurovascular medical technology company with global business operations in over 60 countries.<\/p>\n<p>(20 February 2025)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Raue has advised Lauxera Capital Partners on the due diligence of its 50 million Euro investment in Acandis GmbH. Acandis is a leading German neurovascular medical technology company specialising in the prevention and treatment of strokes. The Lauxera and Acandis transaction represents Lauxera&#8217;s first investment from its second-generation healthcare growth buyout fund, Lauxera Growth II. [&hellip;]<\/p>\n","protected":false},"author":146,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[82],"tags":[],"class_list":["post-18977","post","type-post","status-publish","format-standard","hentry","category-corporate-ma-finance"],"acf":[],"_links":{"self":[{"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/posts\/18977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/users\/146"}],"replies":[{"embeddable":true,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/comments?post=18977"}],"version-history":[{"count":2,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/posts\/18977\/revisions"}],"predecessor-version":[{"id":18981,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/posts\/18977\/revisions\/18981"}],"wp:attachment":[{"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/media?parent=18977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/categories?post=18977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/raue.com\/en\/wp-json\/wp\/v2\/tags?post=18977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}